Plain-English translation of NCT06725706 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This research study uses two types of advanced brain imaging scans (called 18F-92/AV45 and 11C-PIB PET/CT) to detect abnormal protein buildup in the brains of patients with neurodegenerative diseases. Researchers want to understand how well these imaging scans can identify disease and help guide treatment decisions. The study will involve a single injection of a radioactive tracer followed by imaging to measure how much abnormal protein is present in your brain.
Abnormal protein buildup in the brain is linked to neurodegenerative diseases, but doctors need better ways to detect and measure it early. This study aims to determine whether these specialized imaging scans are accurate and reliable tools for identifying disease in patients with various conditions.
You likely qualify if…
You likely don't qualify if…
You will come in for a single visit where you will receive an injection of a radioactive tracer into your vein. Within a specified timeframe after the injection, you will undergo imaging scans (PET/CT or MRI) that take pictures of your brain to measure protein buildup. The entire visit typically takes a few hours, and you will not need to return for additional study visits.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
China
Tianjin Medical University
Collaborators
Tianjin Medical University General Hospital
Enrollment target
~500 participants
Started
September 2012
Primary completion
December 2027
Age range
18 Years – 80 Years
Last updated on clinicaltrials.gov in June 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Ying Wang, MD
Tianjin Medical University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.